CytoMed Therapeutics (NASDAQ: GDTC) director files initial Form 3 ownership

Rhea-AI Filing Summary

CytoMed Therapeutics Ltd director Leong Mark Kei Wei filed an initial Form 3 to report beneficial ownership as an insider of the company. The available data for this filing shows no reported transactions in the issuer’s securities, indicating this is a baseline ownership disclosure rather than a trade report.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Leong Mark Kei Wei

(Last) (First) (Middle)

C/O CYTOMED THERAPEUTICS LIMITED

1 COMMONWEALTH LANE #08-22

(Street)

SINGAPORE 149544

(City) (State) (Zip)

SINGAPORE

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CytoMed Therapeutics Ltd [ GDTC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Mark Kei Wei Leong	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does CytoMed Therapeutics (GDTC) disclose in this Form 3?

The Form 3 identifies Leong Mark Kei Wei as a director and initial reporting person for CytoMed Therapeutics Ltd. It serves as a baseline statement of beneficial ownership when someone first becomes an insider.

Are any stock transactions reported for GDTC in this Form 3?

No transactions are reported. The transaction summary shows zero buys, sells, exercises, gifts, or other movements, indicating this filing only establishes initial ownership status without documenting any trading activity.

Who is the reporting person in CytoMed Therapeutics’ Form 3?

The reporting person is Leong Mark Kei Wei, listed as a director of CytoMed Therapeutics Ltd. As a company insider, he is required to file a Form 3 to disclose his initial beneficial ownership position in the issuer’s securities.

Does this GDTC Form 3 indicate any derivative securities activity?

The filing data shows no derivative transactions and an empty derivative summary. This means there are no reported option exercises, conversions, or other derivative movements associated with this Form 3 at the time of filing.

Why is a Form 3 important for CytoMed Therapeutics investors?

Form 3 filings show when an individual becomes an insider and provides a baseline of their beneficial ownership. This helps investors track future Form 4 and Form 5 filings that will report subsequent trades or changes in that insider’s holdings.